Stay updated on Pembrolizumab + Carboplatin vs Carboplatin in Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Carboplatin vs Carboplatin in Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Carboplatin vs Carboplatin in Breast Cancer Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Added revision note for v3.4.2; the previous funding-lapse notice and revision v3.4.1 were removed.
    Difference
    0.4%
    Check dated 2026-02-11T01:49:09.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a banner informing users about government funding and the NIH Clinical Center's current status. Updated the site to revision v3.4.1, replacing the previous v3.4.0 reference.
    Difference
    0.4%
    Check dated 2026-02-03T22:57:20.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added Show glossary and new data fields (Results First Posted, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, Revision: v3.4.0) and removed the corresponding estimated/older fields (Results First Posted (Estimated), Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4).
    Difference
    0.3%
    Check dated 2026-01-27T16:59:12.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Revision: v3.3.4 was added and Revision: v3.3.3 was removed, indicating a minor version update to the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-20T13:32:07.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Results have been posted (2025-12-22) and the study plan was updated to include cross-over (Arm Bx) and a revised enrollment target of 76 participants. The endpoints and translational components are described in greater detail, including DCR, PFS, ORR, irRECIST-based assessments, and tumor biomarker analyses.
    Difference
    3%
    Check dated 2025-12-29T08:35:38.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    A consolidated Locations section was added with state sites (California, District of Columbia, Illinois, Indiana, Massachusetts, Pennsylvania, Tennessee) and prior state blocks were removed; a new Revision: v3.3.3 tag was introduced.
    Difference
    0.8%
    Check dated 2025-12-22T01:56:38.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Carboplatin vs Carboplatin in Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Carboplatin vs Carboplatin in Breast Cancer Clinical Trial page.